Abstract:Proteolysis targeting chimera (PROTAC) technology, a groundbreaking strategy for degradation of pathogenic proteins by hijacking of the ubiquitin-proteasome-system has become a promising strategy in drug design. However, the real-time monitoring and visualization of protein degradation processes have been long-standing challenges in the realm of drug development. In this research, we sought to amalgamate the highly efficient protein-degrading capabilities of PROTAC technology with the visualization attributes of fluorescent probes, with the potential to pave the path for the design and development of a novel class of visual PROTACs. These novel PROTACs uniquely possess both fluorescence imaging and therapeutic characteristics, all with the goal of enabling real-time observations of protein degradation processes. Our approach involved the utilization of a high ER-targeting fluorescent probe, previously reported in our laboratory, which served as a warhead that specifically binds to the protein of interest (POI). Additionally, a VHL ligand for recruiting E3 ligase and linkers of various lengths were incorporated to synthesize a series of novel ER-inherent fluorescence PROTACs. Among them, compound A3 demonstrated remarkable efficiency in degrading ERα proteins (DC 50 = 0.12 μM) and displaying exceptional anti-proliferative activity against MCF-7 cells (IC 50 = 0.051 μM). Furthermore, it exhibited impressive fluorescence imaging performance, boasting an emission wavelength of up to 582 nm, a Stokes shift of 116 nm, and consistent optical properties. These attributes make it especially suitable for the real-time, in situ tracking of ERα protein degradation processes, thus may serve as a privileged visual theranostic PROTAC for ERα + breast cancer. This study not only broadens the application spectrum of PROTAC technology but also introduces a novel approach for real-time visualization of protein degradation processes, ultimately enhancing the diagnostic and treatment efficacy of PROTACs.

Development of Cell-Permeable Peptide-Based PROTACs Targeting Estrogen Receptor Α

Development of Stabilized Peptide-Based PROTACs Against Estrogen Receptor Α

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

PROTAC Degrader of Estrogen Receptor Α Targeting DNA-Binding Domain in Breast Cancer.

Engineering POLYTAC Nanoparticles for Bioorthogonal Click Reaction-Enforced Protein Degradation and Breast Cancer Therapy

Novel 11Β-Substituted Estradiol Conjugates: Transition from ERα Agonizts to Effective PROTAC Degraders

Discovery of estrogen receptor α targeting caged hypoxia-responsive PROTACs with an inherent bicyclic skeleton for breast cancer treatment

Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras Through Irgd Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer.

Discovery of a Novel Class of PROTACs As Potent and Selective Estrogen Receptor Α Degraders to Overcome Endocrine-Resistant Breast Cancer in Vitro and in Vivo

Selective Protein of Interest Degradation Through the Split-and-Mix Liposome Proteolysis Targeting Chimera Approach.

Glutathione-responsive PROTAC for targeted degradation of ERα in breast cancer cells

PROTAC: novel degradable approach for different targets to treat breast cancer

A modular PROTAC design for target destruction using a degradation signal based on a single amino acid

Mrna PROTACs: Engineering PROTACs for High‐efficiency Targeted Protein Degradation

Fluorescence theranostic PROTACs for real-time visualization of ERα degradation

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Enzyme-catalyzed Activation of Pro-PROTAC for Cell-selective Protein Degradation

Discovery of novel penetrating peptides able to target human leukemia and lymphoma for enhanced PROTAC delivery

Persistent Degradation of HER2 Protein by Hybrid nanoPROTAC for Programmed Cell Death

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Development of a Potent Peptide Inhibitor of Estrogen Receptor Α